ReviewJournal of clinical medicine2021
Fertility-Sparing Treatment of Patients with Endometrial Cancer: A Review of the Literature.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Levonorgestrel-releasing intrauterine system-based therapies for early-stage endometrial cancer: a systematic review and meta-analysis.Journal of gynecologic oncology · 2023Pooled it
- Review
- Incidental endometrial cancer diagnosis during pre-IVF workup: fertility-sparing treatment and embryo preservation.JCEM case reports · 2026Article
- Fertility-Sparing Management of Grade 2 Endometrioid Endometrial Adenocarcinoma Without Progesterone Receptor Expression: A Case Report.Case reports in obstetrics and gynecology · 2026Article
- Residual disease volume and prognosis in endometrioid precancer after progestin therapy.Virchows Archiv : an international journal of pathology · 2025Article
- Fertility Preservation in Early-Stage Endometrial Carcinoma and EIN: A Single-Centre Experience and Literature Review.Cancers · 2025Article
- Epigenetics of Endometrial Cancer: The Role of Chromatin Modifications and Medicolegal Implications.International journal of molecular sciences · 2025Review
- Outcomes of extended progestin therapy in atypical endometrial hyperplasia patients without an initial response to progestin: a retrospective study from two tertiary centers in Korea and Taiwan.Journal of gynecologic oncology · 2025Article
- Fertility Sparing Medical Management Options in Gynecologic Cancers.Current treatment options in oncology · 2025Review
- FedCMC: a federated learning model with contribution fairness based on multi-center core data extraction for assessing the myometrial invasion status of endometrial cancer.Frontiers in oncology · 2025Article
- Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.Current oncology reports · 2024Review
- Advantages of Robotic Surgery for Patients of Reproductive Age with Endometrial Cancer.Life (Basel, Switzerland) · 2024Review
- Article
- Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.World journal of surgical oncology · 2024Article
- Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer.Frontiers in oncology · 2024Review
- Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes.Cancers · 2022Review
- Analysis of IVF/ICSI outcomes in infertile women with early-stage endometrial cancer and atypical endometrial hyperplasia after conservative treatment.Journal of assisted reproduction and genetics · 2022Article
- Endometrial Cancer Management in Young Women.Cancers · 2022Review
- Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is currently the most common malignancy of the female genital tract in developed countries. Although it is more common in postmenopausal women, it may affect up to 25% in the premenopausal age and 3-5% under the age of 40 years. Furthermore, in the last decades a significant shift to pregnancy at older maternal ages, particularly in resource-rich countries, has been observed. Therefore, in this scenario fertility-sparing alternatives should be discussed with patients affected by EC. This study summarizes available literature on fertility-sparing management of patients affected by EC, focusing on the oncologic and reproductive outcomes. A systematic computerized search of the literature was performed in two electronic databases (PubMed and MEDLINE) in order to identify relevant articles to be included for the purpose of this systematic review. On the basis of available evidence, fertility-sparing alternatives are oral progestins alone or in combination with other drugs, levonorgestrel intrauterine system and hysteroscopic resection in association with progestin therapies. These strategies seem feasible and safe for young patients with G1 endometrioid EC limited to the endometrium. However, there is a lack of high-quality evidence on the efficacy and safety of fertility-sparing treatments and future well-designed studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.